Sonomed Escalon™ Announces Release of AXIS™ iPad App

WAYNE, Pa., Feb. 23, 2012 /PRNewswire/ -- Escalon Medical Corp.'s (Nasdaq Market: ESMC) subsidiary,  Sonomed Escalon™ announced the release of its new iPad App for the AXIS™ Image Management System at the recent World Ophthalmology Congress held February 16-20 in Abu Dhabi, UAE.

Matthew Carnevale, Chief Technical Officer, stated that "the AXIS iPad App is an industry first in ophthalmic diagnostic imaging management, and provides an entirely new level of flexibility and power.  A clinician can now view all of their ophthalmic diagnostic images from anywhere at any time on their iPad, including slice-by-slice review of OCT images, fundus images, ultrasound, visual fields and more."  The AXIS iPad App was first displayed pre-release at the American Academy of Ophthalmology meeting held October 22-25 2011 in Orlando FL.  In addition, AXIS and the iPad App were on display in the Heidelberg Engineering booth to showcase the combination of AXIS and the Heidelberg Spectralis OCT/SLO system.  Mr. Carnevale continued, "The response to the powerful combination of the AXIS iPad App and the Heidelberg Spectralis was overwhelming."

AXIS is a web-based image management system accessible from any standard Internet browser that manages all images from any ophthalmic diagnostic device within a single database. The AXIS iPad App seamlessly integrates with AXIS to provide image review capabilities within an efficient and portable platform.

The AXIS iPad App is now available in the Apple App Store. Sonomed Escalon™ is the new combined ophthalmic products brand of Escalon Medical Corp.

Founded in 1987, the Company (www.escalonmed.com) develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company 's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida and Barrow-in-Furness, U.K.

Note:  This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
implement cost reductions,
generate cash,
identify, finance and enter into business relationships and acquisitions. 
ability to continue as a going concern

Other factors include uncertainties and risks related to:

ability to continue as a going concern
new product development, commercialization, manufacturing and market acceptance of new products,
changes and the impact of foreign laws,
marketing acceptance of existing products in new markets,
research and development activities, including failure to demonstrate clinical efficacy,
delays by regulatory authorities, scientific and technical advances by the Company or third parties,
introduction of competitive products,
ability to reduce staffing and other costs and retain benefit of prior reductions
third party reimbursement and physician training,
the effects of asset or other business dispositions and divestments, and
general economic conditions.

Further information about these and other relevant risks and uncertainties may be found in the Company's reports and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

Apple and iPad are trademarks of Apple, Inc. in the US and other countries.

SOURCE Escalon Medical Corp.